Project Grant R01CA316005
Award Date 8/17/26
Completion Date 7/31/31
Dollars Obligated $614K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded a cooperative agreement totaling $681,310 to The Trustees of Columbia University in the City of New York on June 24, 2026, under the Cancer Biology Research program (CFDA 93.396). The funded research investigates mechanisms that promote bone metastasis in prostate cancer, the major cause of death in metastatic prostate cancer patients. Columbia will use genetically-engineered mouse models (GEMMs) to...
- The National Cancer Institute awarded New York University School of Medicine $580,131 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the cellular properties and pathogenesis of double-null prostate cancer through genetically engineered mouse models and analysis of human castration-resistant prostate cancer data. The research examines how aberrant co-activation of HGF/MET and WNT/β-catenin signaling pathways induces prostate tumor growth and...
- The National Cancer Institute awarded Yale University $142,635 under the Cancer Research Manpower program (CFDA 93.398) on June 3, 2026, to support research decoding long noncoding RNA networks in lineage plasticity and androgen receptor-targeted therapy resistance in prostate cancer. The research employs genome-wide CRISPR interference screening targeting approximately 10,000 long noncoding RNAs to identify mechanisms driving resistance to androgen receptor-targeted therapies in metastatic...
- The National Cancer Institute awarded Yale University $560,087 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to define and target mechanisms of the neurolysin-KIF11-WNT3A axis driving therapy resistance in prostate cancer. The award funds research into how prostate cancer cells adapt to androgen receptor-targeted therapies and remodel the tumor microenvironment to undermine therapeutic activity. The work will comprehensively define the molecular mechanisms by...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $637,473 on June 22, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on lineage plasticity in FGFR3-mutant bladder cancer and its role in therapeutic response. The research dissects three integrated aims: mechanistic understanding of how CDK8 and lineage-specifying transcription factors regulate lineage plasticity through genome-wide epigenetic and...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $752,280 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to decode basal cell multipotency as a precursor and therapeutic target in histological transformation across lung cancer subtypes. The award funds research into the molecular and cellular mechanisms driving adenocarcinoma transformation to small cell lung cancer or squamous cell carcinoma histology as a resistance mechanism...
- The National Cancer Institute awarded Weill Medical College of Cornell University $169,291 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the cooperative role of E2F1 and interacting proteins in driving advanced prostate cancer. The project investigates the molecular mechanisms underlying neuroendocrine prostate cancer (NEPC), an aggressive androgen receptor-independent transformation of prostate adenocarcinoma that develops resistance to...
- The National Cancer Institute, under the Department of Health and Human Services, awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $498,775 under Cancer Biology Research (CFDA 93.396) on July 1, 2026. The award funds investigation of targetable mechanisms driving altered cell states in castration-resistant prostate cancer. The project dissects the emergence of a specific cellular subtype in early-stage prostate cancer capable of...
- The National Cancer Institute awarded New York University $169,500 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of LINE-1 retrotransposons in human diseases by mining patient data from the NYU Langone database, which comprises approximately 4.8 million patient records. The research will analyze reverse transcriptase inhibitor-treated patient cohorts against control cohorts to identify differences in disease incidence, integrating...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $448,017 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate prolactin signaling in brain metastasis of HER2-positive breast cancer. The research uses immunocompetent mouse models to elucidate mechanisms enabling HER2-positive breast cancer cells to colonize and thrive in the brain. The work has identified a tumor-pituitary-prolactin axis that drives...